HUTCHMED (China) (HCM) H1 2025 Earnings Call August 07, 2025 08:00 AM ET Speaker0Hello, everyone. This is David Ng, Head of Investor Relations of HutchMet. Thank you for joining HutchMet twenty '25 interim result presentation. Our results and presentation slides have already been posted on our home page as well as on the Hong Kong Stock Exchange website. Just a quick moment on the disclaimer.The performance and results of operation of Hutchinson Group contained within this presentation are historical in nat ...

GLOBAL COMMERCIAL PORTFOLIO NEXT-GENERATION INNOVATIVE PLATFORM 0000po HUTCHMED August 2025 Nasdaq/AIM:HCM | HKEX:13 Safe harbor statement & disclaimer The performance and results of operations of the HUTCHMED Group contained within this presentation are historical in nature, and past performance is no guarantee of future results. apat performance is no guarantee of future results of the Group. This presentation cortains for na d-looking statements filings with the US Securities and Endorge Commis within th ...

Exhibit 99.1 HUTCHMED Reports 2025 Interim Results — Indications expansion driving growth and ATTC platform enriching pipeline — — $455 million in net income attributable to HUTCHMED driven by non-core partial disposal — Hong Kong, Shanghai & Florham Park, NJ — Thursday, August 7, 2025: HUTCHMED (China) Limited ("HUTCHMED", the "Company" or "we") (Nasdaq/AIM:HCM; HKEX:13) today reports its financial results for the six months ended June 30, 2025 and provides updates on key clinical and commercial developmen ...

Core Viewpoint - Hutchison China MediTech Limited (HCM) reported a total revenue of $278 million for the first half of 2025, a decrease of 9.16% year-on-year, while net profit attributable to shareholders surged to $455 million, reflecting a significant increase of 1663.32% [1] Financial Performance - Total revenue for HCM in the first half of 2025 was $278 million, down 9.16% compared to the previous year [1] - Net profit attributable to shareholders reached $455 million, marking a substantial increase of 1663.32% year-on-year [1] - Basic earnings per share for ordinary shares were reported at $0.53 [1] Strategic Developments - HCM's non-executive chairman, Dr. Dan Eldar, emphasized the company's strong financial position and operational strength, indicating readiness for a new growth phase [1] - The company is focusing on collaboration opportunities with multinational pharmaceutical companies, particularly in licensing deals with Chinese biotech firms [1] - HCM plans to deploy resources cautiously yet actively to accelerate the development of candidates from its innovative ATTC platform [1][2] Clinical and Regulatory Milestones - Significant milestones were achieved in the first half of 2025, including impressive data from the SACHI study presented at the ASCO annual meeting, demonstrating clinical benefits for patients with EGFR TKI-resistant lung cancer [1] - The approval for the drug Vorasertib was obtained ahead of expectations, allowing participation in this year's National Medical Insurance Drug List negotiations [1] - HCM's third indication for the drug Aiyoute for kidney cancer has been accepted by the National Medical Products Administration, with data to be presented at the ESMO annual meeting [1] Future Outlook - The company anticipates a rebound in sales growth in the second half of 2025, driven by the expansion of indications in China and increased penetration in overseas markets [2] - HCM is advancing multiple candidates from its key ATTC technology platform into clinical development, which is expected to enrich its product pipeline and create more collaboration opportunities [2]

Core Insights - HUTCHMED reported a significant increase in net income to $455 million for the first half of 2025, primarily due to a $416.3 million gain from the divestment of a non-core joint venture [5][33][31] - The company is expanding its pipeline with new drug candidates from its Antibody-Targeted Therapy Conjugate (ATTC) platform, which is expected to enter clinical development by late 2025 [19][20][6] Financial Performance - Total revenue for the six months ended June 30, 2025, was $277.7 million, a decrease from $305.7 million in the same period of 2024 [29][10] - Oncology/Immunology consolidated revenue was $143.5 million, down from $168.7 million in H1 2024, reflecting competitive pressures and changes in sales strategy [10][32] - The company achieved a cash balance of $1.36 billion as of June 30, 2025, up from $836.1 million at the end of 2024 [34] Commercial Operations - FRUZAQLA's in-market sales increased by 25% to $162.8 million, driven by expansion into over 30 countries [5][8] - ELUNATE's in-market sales decreased to $43.0 million, reflecting competitive pressures, while SULANDA's sales dropped by 50% to $12.7 million due to competition from new therapies [12][32] - ORPATHYS revenue decreased to $9.0 million, impacted by competition despite recent approvals for new indications [32][10] Pipeline and Clinical Development - ORPATHYS received approval for a third lung cancer indication, which is expected to be eligible for national reimbursement negotiations [5][6] - Positive results from the SACHI and SAVANNAH trials for ORPATHYS were presented at major conferences, showing significant improvements in progression-free survival compared to chemotherapy [5][7] - The company plans to initiate clinical trials for multiple ATTC drug candidates by late 2025, leveraging its expertise in targeted therapies [19][20] Regulatory Updates - The company has streamlined its sales force to enhance productivity and adapt to the evolving competitive landscape in the pharmaceutical sector [9][10] - HUTCHMED is focusing on science-driven commercial activities to differentiate its products amid increasing competition [9][10] Collaboration and Strategic Focus - HUTCHMED aims to partner with multinational pharmaceutical companies to explore licensing opportunities, reflecting a favorable market sentiment towards Chinese biotech [6][7] - The company is actively deploying resources to expedite the development of drug candidates from its ATTC platform, which is expected to create collaboration opportunities [7][19]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性或完整性亦不發表任何聲明，並明確表示， 概不對因本公告全部或任何部分內容而產生或因倚賴該等內容而引致的任何損失承擔任何責任。 HUTCHMED (China) Limited 和黃醫藥（中國）有限公司 （於開曼群島註冊成立的有限公司） （股份代號：13） 和黃醫藥公佈2025年中期業績 — 適應症擴展推動增長及ATTC平台為管線注入新活力 — 出售非核心業務部分股權為和黃醫藥帶來4.55億美元應佔淨收益 — 和黃醫藥（中國）有限公司（簡稱「和黃醫藥」、「本公司」或「我們」）今日公佈截至2025年6月30日止六個月 的財務業績以及提供關鍵臨床項目和商業化發展的最新進展。 和黃醫藥將於今天2025年8月7日（星期四）美國東部夏令時間上午8時/ 英國夏令時間下午1時/ 中國香港時間晚 上8時舉行業績會網絡直播（英語場次），並於明天2025年8月8日（星期五）中國香港時間上午8時30分舉行中 文（普通話）場次。 投資者可於www.hutch-med.com/event登記後參與實時網絡直播。 除另有說明外，所有金額均以美元列示。縮寫清單 ...

Group 1 - The stock price of Hutchison China MediTech Limited (HCM) increased by 5.03% to $18.15 per share, with a total market capitalization of $3.166 billion as of August 5 [1] - For the fiscal year ending December 31, 2024, the company reported total revenue of $630 million, a decrease of 24.8% year-over-year, and a net profit attributable to shareholders of $37.729 million, down 62.56% year-over-year [1] - The company is scheduled to release its interim report for the fiscal year 2025 on August 7, 2023, before the market opens in the Eastern Time zone [1] Group 2 - Hutchison China MediTech Limited is one of the first innovative pharmaceutical research and development companies in China focused on the global market [2] - Over the past 20 years, the company has established a comprehensive and integrated research and development platform with world-class discovery and development capabilities [2] - The company has successfully launched three self-discovered anti-tumor candidate drugs in China, with the first drug also approved in the United States [2] - Hutchison China MediTech has built a profitable commercial platform in China for the production, marketing, and distribution of its innovative oncology drugs, prescription drugs, and consumer healthcare products [2] - The company is listed on the NASDAQ Global Select Market, Hong Kong Stock Exchange, and AIM market of the London Stock Exchange [2]

Core Insights - HCM's stock opened up by 3.41% on August 5, reaching $17.87 per share with a total market capitalization of $3.117 billion [1] - For the fiscal year ending December 31, 2024, HCM reported total revenue of $630 million, a decrease of 24.8% year-over-year, and a net profit attributable to shareholders of $37.729 million, down 62.56% year-over-year [1] - HCM is scheduled to release its mid-year report for fiscal year 2025 on August 7, prior to the market opening [1] Company Overview - HCM is recognized as one of China's first innovative pharmaceutical research and development companies focused on the global market [2] - Over the past 20 years, the company has established a comprehensive and integrated R&D innovation platform with world-class discovery and development capabilities [2] - HCM is dedicated to bringing its self-discovered anti-tumor candidate drugs to global patients, with three drugs already launched in China and the first drug also available in the U.S. [2] - The company has built a profitable commercial platform in China for the production, marketing, and distribution of its innovative oncology drugs, prescription drugs, and consumer healthcare products [2] - HCM is listed on the NASDAQ Global Select Market, the Hong Kong Stock Exchange, and the AIM market of the London Stock Exchange [2]

Core Viewpoint - The article discusses the increasing interest of Hong Kong buyers in real estate in the Greater Bay Area, particularly in cities like Huizhou and Zhongshan, due to lower property prices and appealing living conditions [1][2][3]. Group 1: Market Trends - Hong Kong buyers are expanding their property search to the entire Greater Bay Area, with a notable interest in Huizhou's coastal properties due to their lower total prices [1]. - Recent projects promoted by Cheung Kong Property include approximately 400 units across four developments, with Huizhou Longbo Garden offering 300 units [1][2]. - The price of a 51-square-meter unit in Huizhou Longbo Garden is around 440,000 yuan, translating to approximately 8,554 yuan per square meter, significantly lower than previous prices of 10,400 to 14,000 yuan per square meter [1]. Group 2: Buyer Preferences - Many Hong Kong buyers are looking for properties priced under 4 million yuan, primarily for self-use, and are cautious about high total prices [3]. - The appeal of properties in Huizhou and Zhongshan is driven by their suitability for retirement, offering larger living spaces and scenic views at a fraction of the cost compared to Hong Kong [2]. Group 3: Market Dynamics - The decline in property prices in Huizhou, Zhongshan, and Dongguan has made these areas more attractive to Hong Kong buyers, with significant negotiation flexibility in the market [1][2]. - The Hong Kong real estate market is showing signs of recovery, with a slight decrease in property registrations indicating active trading, driven by factors such as "super rebound" and optimistic economic outlooks [3].

Core Viewpoint - Li Ka-shing's Cheung Kong Property is selling 400 residential units in the Greater Bay Area at significantly reduced prices, with the cheapest unit priced at 400,000 yuan, indicating a strategic move to capitalize on market conditions and demand from Hong Kong buyers [2][5]. Group 1: Property Sales Strategy - The properties being sold are primarily older developments, with many having been acquired at low land costs years ago, allowing for substantial profit margins even at reduced prices [5][8]. - The pricing strategy is attractive, with units in Dongguan's Haiyi Haoting seeing price drops from 44,000 to 18,000-36,000 yuan per square meter, effectively halving the price [6][8]. - The sales are driven by a surge in demand from Hong Kong residents, who find the price difference compelling, as new homes in Hong Kong average around 200,000 yuan per square meter [5][6]. Group 2: Market Trends and Demand - The trend of Hong Kong residents purchasing properties in Guangdong has been increasing, with 3,341 transactions recorded by June 2023, amounting to 3.08 billion yuan [5][6]. - The development of the "one-hour living circle" in the Greater Bay Area is facilitating this trend, as more Hong Kong residents are willing to commute for work and leisure [5][8]. - The shift in buyer motivation from investment to self-occupation is notable, with buyers now prioritizing living conditions and amenities [8]. Group 3: Financial Strategy and Asset Management - The primary reason for the aggressive selling strategy appears to be the need for cash flow, as Cheung Kong's sales revenue in mainland China is projected to drop by 87% in 2024 compared to 2020 [7][8]. - Selling properties allows the company to mitigate risks associated with holding onto unsold inventory, especially in a market where some cities have inventory turnover periods exceeding 30 months [8]. - The sale of properties aligns with Li Ka-shing's long-standing strategy of capitalizing on favorable market conditions while managing financial risks effectively [12][13]. Group 4: Broader Strategic Adjustments - The sale of port assets by Li Ka-shing in recent years reflects a broader strategic shift in response to changing global trade dynamics and the need to reallocate resources to more promising sectors [9][10][12]. - The funds generated from asset sales are being redirected towards investments in technology and renewable energy, indicating a proactive approach to adapting to market changes [12][13]. - Overall, the company's actions demonstrate a calculated balance between risk management and seizing short-term opportunities in the real estate market [13].